Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases (Q28727917)

29 October 2023

Charles C L Tong

1

Charles C L

Tong

1 reference

29 October 2023

Max W Sung

3

Max W

Sung

1 reference

29 October 2023

Jamie A Cesaretti

4

Jamie A

Cesaretti

1 reference

29 October 2023

Richard G Stock

5

Richard G

Stock

1 reference

29 October 2023

Stuart H Packer

6

Stuart H

Packer

1 reference

29 October 2023

Kevin Forsythe

7

Kevin

Forsythe

1 reference

29 October 2023

Eric M Genden

8

Eric M

Genden

1 reference

29 October 2023

Myron Schwartz

9

Myron

Schwartz

1 reference

29 October 2023

K H Vincent Lau

10

K H Vincent

Lau

1 reference

29 October 2023

Matthew Galsky

11

Matthew

Galsky

1 reference

29 October 2023

Junko Ozao-Choy

12

Junko

Ozao-Choy

1 reference

29 October 2023

Shu-Hsia Chen

13

Shu-Hsia

Chen

1 reference

29 October 2023

Johnny Kao

14

Johnny

Kao

1 reference

Creative Commons Attribution 4.0 International

29 October 2023

language of work or name

English

0 references

publication date

2012

0 references

published in

PLOS One

0 references

volume

7

0 references

issue

6

0 references

page(s)

e36979

0 references

copyright license

start time

27 June 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Cetuximab for the treatment of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Erlotinib in previously treated non-small-cell lung cancer

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

HPV-induced oropharyngeal cancer, immune response and response to therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Phase I study of individualized stereotactic body radiotherapy of liver metastases.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Normal tissue toxicity after small field hypofractionated stereotactic body radiation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

A rationale for the targeted treatment of oligometastases with radiotherapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Sunitinib: from rational design to clinical efficacy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

The concurrent chemoradiation paradigm--general principles

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

Postoperative radiotherapy for lung cancer: the breast cancer story all over again?

20 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0036979

Combined effects of angiostatin and ionizing radiation in antitumour therapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0036979

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0036979

Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3384658

An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease

27 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761653

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761653

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22761653

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0036979

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

709283

ADS bibcode

2012PLoSO...736979T

0 references

OpenCitations bibliographic resource ID

709283

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

709283

PMC publication ID

3384658

0 references